Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif., May 13, 2026–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.Read More